27.4 C
New York
Saturday, September 6, 2025
HomeFinTechStarpharma: Continues VIRALEZE success in December quarter

Starpharma: Continues VIRALEZE success in December quarter

Starpharma Continues VIRALEZE success in December quarter

  • Starpharma (SPL) releases its September quarterly report, with the period again highlighted by the continued success of VIRALEZE
  • In late July, VIRALEZE showed a reduction of more than 99.99 per cent against the Delta variant of SARS-CoV-2, the virus that causes COVID-19
  • The VIRALEZE antiviral nasal spray is expected to be launched in Vietnam and Italy next month and SPL is in discussions with other markets in Asia, Europe and India
  • As of September 30, the platform had more than $53.61 million in total available funding, representing 7.6 quarters of use if spending levels remain the same
  • The platform is steady on the market with shares trading at $1.07
RELATED ARTICLES
- Advertisment -

Most Popular

Recent Comments